Cancer NetworkOriginal article
<![CDATA[Iberdomide Combination Doubles PFS vs SOC Therapy in R/R Multiple Myeloma]]>
Phase 3positiveIberdomideDaratumumabDexamethasonePositive
AI Analysis
Summary
Iberdomide in combination with daratumumab and dexamethasone met the second dual primary endpoint for progression-free survival in the Phase 3 EXCALIBER-RRMM trial for relapsed/refractory multiple myeloma, demonstrating superiority over standard of care.
Clinical Trial Data
Phase
3
Primary Endpoint
Met
Outcome Details
Iberdomide plus daratumumab/dexamethasone met the second dual primary endpoint of progression-free survival versus standard of care therapy in EXCALIBER-RRMM trial
Importance:7/10
Sentiment:
0.80
multiple myelomaPhase 3combination therapyPFSrelapsed/refractory
Related Companies
Read the original article
Published by Cancer Network on October 8, 2026 3:00 PM